Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Multiple Myeloma
NCT00003511Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Apr 1996
- Primary completion
- Oct 1999
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in multiple myeloma (MM), sponsored by Burzynski Research Institute. Started Apr 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00003511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003511.